116 related articles for article (PubMed ID: 9303556)
1. Proadrenomedullin N-terminal 20 peptide (PAMP) inhibits proliferation of human neuroblastoma TGW cells.
Ando K; Omi N; Shimosawa T; Fujita T
FEBS Lett; 1997 Aug; 413(3):462-6. PubMed ID: 9303556
[TBL] [Abstract][Full Text] [Related]
2. A newly identified peptide, proadrenomedullin N-terminal 20 peptide, induces hypotensive action via pertussis toxin-sensitive mechanisms.
Shimosawa T; Ando K; Fujita T
Hypertension; 1997 Nov; 30(5):1009-14. PubMed ID: 9369247
[TBL] [Abstract][Full Text] [Related]
3. Proadrenomedullin N-terminal 20 peptide inhibits aldosterone secretion of human adrenocortical and Conn's adenoma cells: comparison with adrenomedullin effect.
Andreis PG; Tortorella C; Mazzocchi G; Nussdorfer GG
J Clin Endocrinol Metab; 1998 Jan; 83(1):253-7. PubMed ID: 9435451
[TBL] [Abstract][Full Text] [Related]
4. Proadrenomedullin NH(2)-terminal 20 peptide (PAMP) and adrenomedullin bind to teratocarcinoma cells.
Moody TW; Coy D; Cuttitta F; Montuenga LM
Peptides; 2000 Jan; 21(1):101-7. PubMed ID: 10704725
[TBL] [Abstract][Full Text] [Related]
5. Proadrenomedullin NH2-terminal 20 peptide inhibits the voltage-gated Ca2+ channel current through a pertussis toxin-sensitive G protein in rat pheochromocytoma-derived PC 12 cells.
Takano K; Yamashita N; Fujita T
J Clin Invest; 1996 Jul; 98(1):14-7. PubMed ID: 8690785
[TBL] [Abstract][Full Text] [Related]
6. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) in adrenal chromaffin cells.
Kobayashi H; Yanagita T; Yokoo H; Wada A
Peptides; 2001 Nov; 22(11):1895-901. PubMed ID: 11754978
[TBL] [Abstract][Full Text] [Related]
7. Adrenomedullin inhibits transmural pressure induced mesangial cell proliferation through activation of protein kinase A.
Osajima A; Kato H; Uezono Y; Suda T; Okazaki M; Oishi Y; Tamura M; Tanaka H; Izumi F; Nakashima Y
Nephron; 1999; 83(4):352-7. PubMed ID: 10575297
[TBL] [Abstract][Full Text] [Related]
8. Proadrenomedullin NH(2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings.
Shimosawa T; Ito Y; Ando K; Kitamura K; Kangawa K; Fujita T
J Clin Invest; 1995 Sep; 96(3):1672-6. PubMed ID: 7657838
[TBL] [Abstract][Full Text] [Related]
9. The vasorelaxant effect of adrenomedullin, proadrenomedullin N-terminal 20 peptide and amylin in human skin.
Hasbak P; Eskesen K; Lind H; Holst J; Edvinsson L
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):162-7. PubMed ID: 16918718
[TBL] [Abstract][Full Text] [Related]
10. Effects of adrenomedullin and proadrenomedullin N-terminal 20 peptide on rat zona glomerulosa cells.
Andreis PG; Mazzocchi G; Rebuffat P; Nussdorfer GG
Life Sci; 1997; 60(19):1693-7. PubMed ID: 9129124
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by adrenomedullin of the adrenergic neurogenic response in canine mesenteric arteries.
Okamura T; Zhang JX; Kangawa K; Toda N
Jpn J Pharmacol; 1997 Mar; 73(3):259-61. PubMed ID: 9127823
[TBL] [Abstract][Full Text] [Related]
12. Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat.
Champion HC; Murphy WA; Coy DH; Kadowitz PJ
Am J Physiol; 1997 Apr; 272(4 Pt 2):R1047-54. PubMed ID: 9140000
[TBL] [Abstract][Full Text] [Related]
13. Elevation of circulating proadrenomedullin-N terminal 20-peptide in thyrotoxicosis.
Taniyama M; Kitamura K; Ban Y; Sugita E; Ito K; Katagiri T
Clin Endocrinol (Oxf); 1997 Mar; 46(3):271-4. PubMed ID: 9156034
[TBL] [Abstract][Full Text] [Related]
14. Central mechanisms for the hypertensive effects of preproadrenomedullin-derived peptides in conscious rats.
Samson WK; Murphy TC; Resch ZT
Am J Physiol; 1998 May; 274(5):R1505-9. PubMed ID: 9612421
[TBL] [Abstract][Full Text] [Related]
15. Hypotensive effect of a newly identified peptide, proadrenomedullin N-terminal 20 peptide.
Shimosawa T; Fujita T
Hypertension; 1996 Sep; 28(3):325-9. PubMed ID: 8794811
[TBL] [Abstract][Full Text] [Related]
16. Involvement of cAMP-dependent protein kinase and pertussis toxin-sensitive G-proteins in CGRP mediated JNK activation in human neuroblastoma cell line.
Disa J; Parameswaran N; Nambi P; Aiyar N
Neuropeptides; 2000; 34(3-4):229-33. PubMed ID: 11021985
[TBL] [Abstract][Full Text] [Related]
17. CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.
Hasbak P; Sams A; Schifter S; Longmore J; Edvinsson L
Br J Pharmacol; 2001 Aug; 133(8):1405-13. PubMed ID: 11498528
[TBL] [Abstract][Full Text] [Related]
18. Effect of vasoactive peptides in Tetrahymena: chemotactic activities of adrenomedullin, proadrenomedullin N-terminal 20 peptide (PAMP) and calcitonin gene-related peptide (CGRP).
Kőhidai L; Tóth K; Samotik P; Ranganathan K; Láng O; Tóth M; Ruskoaho H
Mol Cell Biochem; 2016 Jan; 411(1-2):271-80. PubMed ID: 26481478
[TBL] [Abstract][Full Text] [Related]
19. Central action of adrenomedullin to inhibit gastric emptying in rats.
Martínez V; Cuttitta F; Taché Y
Endocrinology; 1997 Sep; 138(9):3749-55. PubMed ID: 9275061
[TBL] [Abstract][Full Text] [Related]
20. Distribution and molecular forms of adrenomedullin and proadrenomedullin N-terminal 20 peptide in the porcine gastrointestinal tract.
Kiyomizu A; Kitamura K; Kawamoto M; Eto T
J Gastroenterol; 2001 Jan; 36(1):18-23. PubMed ID: 11211206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
